PATHWAY PROFILING ANTIBODIES & REAGENTS

     
Products
Product : Antibody >> Cancer Antibodies , Chromatin , Hormones and Growth Facto.. , Neurobiology , New Antibodies >> Androgen Receptor (Ser213/210)
      
 

Monoclonal Antibody to Androgen Receptor (Ser213/210)

 
Cat. No.DescriptionFormatUnitPrice(USD)QuantityBulk Quotation
IMG-561
Androgen Receptor (Ser213/210)Purified
0.1 mg
 --
 
Catalog No: IMG-561
Imgenex is now a part of Novus Biologicals! All orders, billing and shipments will be received from Novus. Please contact Novus directly for any questions – novus@novusbio.com. To insure proper processing of you order, please insure that your purchase orders show Novus Biologicals as the vendor.
Contents: 0.1 mg in 0.2 ml PBS containing 0.05% BSA and 0.05% sodium azide. Sodium azide is highly toxic.
Isotype: Mouse IgG1, Kappa
Clone: 156C135.2
Purification: Protein G Chromatography
Species: Human, New World monkey
Predicted React: Chimpanzee, Dog, Mouse, Pig, Rat
Host: Mouse
Application: IHC (paraffin): See Lin et al, 2007 for details.
Western blot analysis: 1-4 ug/ml
Storage: Store at 4°C. For long-term storage, store at -20°C.
Recommended
Positive Control:
IGF-1 stimulated LNCaP
 

Background
The androgen receptor (AR) is an ~110 kDa androgen-dependent transcription factor that is a member of the steroid/nuclear receptor gene superfamily.  The AR signaling pathway plays a key role in development and function of male reproductive organs, including the prostate and epididymis. AR also plays a role in nonreproductive organs, such as muscle, hair follicles, and brain.  Abnormalities in the AR signaling pathway have been linked to a number of diseases, including prostate cancer, Kennedy's disease and male infertility.   The PI3K/Akt signaling pathway plays an important role in regulating AR activity through phosphorylation of AR at Ser213/210 and Ser791/790.  Growth factors or cytokines may induce phosphorylation of AR through the PI3K/Akt pathway.  IGF-1 activates the  phosphatidylinositol 3-kinase(PI3K)/AKT pathway in LNCap at high passage number and increases phosphorylation of of  AR at Ser213/210 (see western blot) and Ser791/790 (Lin et al. 2003).  The western blot results also show that inhibition of the PI3K/Akt pathway by LY294002 prior to incubation with IGF-1 suppressed AR phosphorylation at Ser213/210.  Activation of the PI3K/AKt pathway is thought to have a survival role in prostate cancer by protecting cells from apoptosis. 

Antigen
This antibody was developed against a synthetic peptide corresponding to amino acids 207-221 (GRAREAS*GAPTSSKD) of human androgen receptor, containing the serine 213 phosphorylation site: GenBank Accession No. A39248.  Note: S* refers to phosphorylated serine in the peptide sequence.

Application Notes
In IGF-1 stimulated LNCaP cells (passage number 38), a ~110 kDa band was observed.  Please see Lin et al. 2003 for additional details. The serine phosphorylation site recognized by this antibody has been alternatively referred to Ser213 (Lee and Chang, 2003) and Ser210 (Lin et al, 2003).  Variations in denotation can arise from how the sequence is counted in various GenBank accession numbers.  The site is denoted as Ser213 in GenBank Accession No. A39248, which was used to design the immunogen.

Genebank Info (Protein): NP_000035
Gene ID: 367
SwissProt: P10275
 
Androgen Receptor (Ser213/210) Antibody

LNCaP cells (passage number 38) were serum-starved for 2 days.  After serum starvation, cells were (A) left untreated, (B) treated with 100 ng/ml IGF-1 for 4h, or (C) incubated with 20 um LY294002 for 30 min prior to treatment with 100 ng/ml IGF-1 for 4 h.  (See Lin, H-K., Y-C Hu, L. Yang, S. Altuwaijri. 2003 Fig. 2)

-

Reference
1. Dong, KL and C Chang. 2003. Expression and degradation of androgen receptor: mechanism and clinical implication. J Clinical Endrocrinology & Metabolism. 88:4043-4054.


Research purposes only. Not for diagnostic or in vivo use. This product is guaranteed to perform as indicated on the datasheet for one year from the date of purchase.


Products

Services

Resources

Purchasing

Company

  • What's New
  • Reporter Cells
  • Screening Services
  • Interactive Pathways